Press brief by Jeffrey Jones, MD, MPH of the The Ohio State University, Columbus, OH, on a cross-study analysis of treatment outcomes of 243 patients with 17p del CLL treated with ibrutinib at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.